4.7 Article

Detection and Characterization of a Novel Subset of CD8+CD57+ T Cells in Metastatic Melanoma with an Incompletely Differentiated Phenotype

Journal

CLINICAL CANCER RESEARCH
Volume 18, Issue 9, Pages 2465-2477

Publisher

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-11-2034

Keywords

-

Categories

Funding

  1. National Cancer Institute [R01-CA111999]
  2. University of Texas MD Anderson Cancer Center [P30-CA16672]
  3. National Center for Research Resources [TL1RR024147]
  4. Melanoma SPORE Developmental grant [P50-CA093459-05-DRP21]
  5. Melanoma Research Alliance (MRA)
  6. Mulva Foundation

Ask authors/readers for more resources

Purpose: Tumor-specific T cells are frequently induced naturally in melanoma patients and infiltrate tumors. It is enigmatic why these patients fail to experience tumor regression. Given that CD8(+) T cells mediate antigen-specific killing of tumor cells, the focus of this study was to identify alterations in the differentiation of CD8(+) residing at the tumor site, with emphasis on a population expressing CD57, a marker for terminal differentiation. Experimental Design: We conducted flow cytometric analysis of CD8(+) tumor-infiltrating lymphocytes (TIL) isolated from 44 resected melanoma metastases with known T-cell differentiation markers. For comparison, peripheral blood mononuclear cells were isolated from matched melanoma patients. We sorted different CD8(+) subsets found in TIL and determined their effector functions. In addition, we carried out V beta clonotype expression analysis of T-cell receptors to determine lineage relationship between the CD8(+) TIL subsets. Results: The majority of CD8(+) TIL was in the early-effector memory stage of differentiation. A significant population consisted of an oligoclonal subset of cells coexpressing CD27, CD28, CD57, and Granzyme B, with little or no perforin. These cells could be induced to proliferate, produce a high level of IFN-gamma, and differentiate into CD27(-)CD57(+), perforin(high) mature CTL in vitro. Addition of TGF-beta 1 prevented further differentiation. Conclusions: Our studies identified a novel subset of incompletely differentiated CD8(+) CTL coexpressing early effector memory and late CTL markers. This population resembles that found in patients with uncontrolled chronic viral infections. TGF-beta 1, frequently produced by melanoma tumors, may be a key cytokine inhibiting further maturation of this subset. Clin Cancer Res; 18(9); 2465-77. (C) 2012 AACR.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression

Lu Huang, Shruti Malu, Jodi A. McKenzie, Miles C. Andrews, Amjad H. Talukder, Trang Tieu, Tatiana Karpinets, Cara Haymaker, Marie-Andree Forget, Leila J. Williams, Zhe Wang, Rina M. Mbofung, Zhi-Qiang Wang, Richard Eric Davis, Roger S. Lo, Jennifer A. Wargo, Michael A. Davies, Chantale Bernatchez, Timothy Heffernan, Rodabe N. Amaria, Anil Korkut, Weiyi Peng, Jason Roszik, Gregory Lizee, Scott E. Woodman, Patrick Hwu

CLINICAL CANCER RESEARCH (2018)

Article Multidisciplinary Sciences

General Prediction of Peptide-MHC Binding Modes Using Incremental Docking: A Proof of Concept

Dinler A. Antunes, Didier Devaurs, Mark Moll, Gregory Lizee, Lydia E. Kavraki

SCIENTIFIC REPORTS (2018)

Article Multidisciplinary Sciences

RNA editing derived epitopes function as cancer antigens to elicit immune responses

Minying Zhang, Jens Fritsche, Jason Roszik, Leila J. Williams, Xinxin Peng, Yulun Chiu, Chih-Chiang Tsou, Franziska Hoffgaard, Valentina Goldfinger, Oliver Schoor, Amjad Talukder, Marie A. Forget, Cara Haymaker, Chantale Bernatchez, Leng Han, Yiu-Huen Tsang, Kathleen Kong, Xiaoyan Xu, Kenneth L. Scott, Harpreet Singh-Jasuja, Greg Lizee, Han Liang, Toni Weinschenk, Gordon B. Mills, Patrick Hwu

NATURE COMMUNICATIONS (2018)

Article Oncology

Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8+ T Cells and Synergizes with PI3Kβ Inhibition in PTEN Loss Melanoma

Weiyi Peng, Leila J. Williams, Chunyu Xu, Brenda Melendez, Jodi A. McKenzie, Yuan Chen, Heather L. Jackson, Kui S. Voo, Rina M. Mbofung, Sara Elizabeth Leahey, Jian Wang, Gregory Lizee, Hussein A. Tawbi, Michael A. Davies, Axel Hoos, James Smothers, Roopa Srinivasan, Elaine M. Paul, Niranjan Yanamandra, Patrick Hwu

CLINICAL CANCER RESEARCH (2019)

Article Multidisciplinary Sciences

Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers

Sherille D. Bradley, Amjad H. Talukder, Ivy Lai, Rebecca Davis, Hector Alvarez, Herve Tiriac, Minying Zhang, Yulun Chiu, Brenda Melendez, Kyle R. Jackson, Arjun Katailiha, Heather M. Sonnemann, Fenge Li, Yaan Kang, Na Qiao, Bih-Fang Pan, Philip L. Lorenzi, Mark Hurd, Elizabeth A. Mittendorf, Christine B. Peterson, Milind Javle, Christopher Bristow, Michael Kim, David A. Tuveson, David Hawke, Scott Kopetz, Robert A. Wolff, Patrick Hwu, Anirban Maitra, Jason Roszik, Cassian Yee, Gregory Lizee

NATURE COMMUNICATIONS (2020)

Article Multidisciplinary Sciences

NLRC5/CITA expression correlates with efficient response to checkpoint blockade immunotherapy

Sayuri Yoshihama, Steven X. Cho, Jason Yeung, Xuedong Pan, Gregory Lizee, Kranti Konganti, Valen E. Johnson, Koichi S. Kobayashi

Summary: The expression of NLRC5 and MHC class I-related genes is crucial for the effective response of melanoma patients to anti-CTLA-4 and anti-PD1 checkpoint blockade immunotherapy, serving as potential predictive biomarkers for prognosis and treatment response.

SCIENTIFIC REPORTS (2021)

Article Immunology

IL-1α Mediates Innate and Acquired Resistance to Immunotherapy in Melanoma

Shubhra Singh, Zhilan Xiao, Karishma Bavisi, Jason Roszik, Brenda D. Melendez, Zhiqiang Wang, Mark J. Cantwell, Richard E. Davis, Greg Lizee, Patrick Hwu, Sattva S. Neelapu, Willem W. Overwijk, Manisha Singh

Summary: The study demonstrates that the IL-1 alpha signaling pathway plays a crucial role in melanoma resistance to immunotherapy. Targeting the IL-1 signaling pathway could enhance the efficacy of immunotherapies against melanoma.

JOURNAL OF IMMUNOLOGY (2021)

Review Oncology

Exploiting Tumor Neoantigens to Target Cancer Evolution: Current Challenges and Promising Therapeutic Approaches

Ravi G. Gupta, Fenge Li, Jason Roszik, Gregory Lizee

Summary: Immunotherapeutic manipulation targets genomic instability in cancer by activating T cells, but tumors can evade immune recognition through immunoediting and immunosuppressive mechanisms. Challenges in neoantigen-directed therapy include low frequency of immunogenic neoantigens and tumor cell immune evasion mechanisms.

CANCER DISCOVERY (2021)

Article Oncology

Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations

Fenge Li, Ligang Deng, Kyle R. Jackson, Amjad H. Talukder, Arjun S. Katailiha, Sherille D. Bradley, Qingwei Zou, Caixia Chen, Chong Huo, Yulun Chiu, Matthew Stair, Weihong Feng, Aleksander Bagaev, Nikita Kotlov, Viktor Svekolkin, Ravshan Ataullakhanov, Natalia Miheecheva, Felix Frenkel, Yaling Wang, Minying Zhang, David Hawke, Ling Han, Shuo Zhou, Yan Zhang, Zhenglu Wang, William K. Decker, Heather M. Sonnemann, Jason Roszik, Marie-Andree Forget, Michael A. Davies, Chantale Bernatchez, Cassian Yee, Roland Bassett, Patrick Hwu, Xueming Du, Gregory Lizee

Summary: The phase I trial of personalized NeoAg peptide vaccination in NSCLC patients showed feasibility and safety. Clinical and immune responses following vaccination suggest that EGFR mutations are shared, immunogenic neoantigens with promising therapeutic potential for NSCLC patients. PPV with concurrent EGFR inhibitor therapy was well tolerated and contributed to the induction of T cell responses.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Review Cell Biology

Evolution of CD8+ T Cell Receptor (TCR) Engineered Therapies for the Treatment of Cancer

Yimo Sun, Fenge Li, Heather Sonnemann, Kyle R. Jackson, Amjad H. Talukder, Arjun S. Katailiha, Gregory Lizee

Summary: Engineered TCR-T cell therapy has revolutionized the treatment of human cancer by targeting tumor antigen-specific adaptable cellular products. However, challenges such as low TCR avidity, off-target toxicities, and target antigen loss have limited the efficacy of TCR-T therapy for solid tumors. Further research is needed to address these limitations and improve the safety and efficacy of TCR-T therapies.

CELLS (2021)

Article Oncology

Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity

Yared Hailemichael, Daniel H. Johnson, Noha Abdel-Wahab, Wai Chin Foo, Salah-Eddine Bentebibel, May Daher, Cara Haymaker, Khalida Wani, Chantal Saberian, Dai Ogata, Sang T. Kim, Roza Nurieva, Alexander J. Lazar, Hamzah Abu-Sbeih, Faisal Fa'ak, Antony Mathew, Yinghong Wang, Adewunmi Falohun, Van Trinh, Chrystia Zobniw, Christine Spillson, Jared K. Burks, Muhammad Awiwi, Khaled Elsayes, Luisa Solis Soto, Brenda D. Melendez, Michael A. Davies, Jennifer Wargo, Jonathan Curry, Cassian Yee, Gregory Lizee, Shalini Singh, Padmanee Sharma, James P. Allison, Patrick Hwu, Suhendan Ekmekcioglu, Adi Diab

Summary: Immune checkpoint blockade therapy can cause immune-related adverse events. IL-6 expression is higher in colitis and Th17 cells are more prevalent in immune-related enterocolitis. Anti-CTLA-4 induces stronger Th17 memory in colitis than anti-PD-1. In mouse models, IL-6 blockade enhances tumor control and increases CD4(+)/CD8(+) effector T cell density, while reducing Th17, macrophages, and myeloid cells. Combined IL-6 blockade and ICB enhances tumor rejection and mitigates EAE symptoms. IL-6 blockade with ICB can decouple autoimmunity from antitumor immunity.

CANCER CELL (2022)

Article Oncology

Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma

Chantal Saberian, Rodabe N. Amaria, Amer M. Najjar, Laszlo G. Radvanyi, Cara L. Haymaker, Marie-Andree Forget, Roland L. Bassett, Silvana C. Faria, Isabella C. Glitza, Enrique Alvarez, Sapna Parshottam, Victor Prieto, Gregory Lizee, Michael K. Wong, Jennifer L. McQuade, Adi Diab, Cassian Yee, Hussein A. Tawbi, Sapna Patel, Elizabeth J. Shpall, Michael A. Davies, Patrick Hwu, Chantale Bernatchez

Summary: The combination of adoptive transfer of tumor-infiltrating lymphocytes (TIL) and dendritic cells (DC) did not show significant difference in the persistence of MART-1-specific TIL compared to TIL therapy alone. Although more patients showed clinical response to TIL+DC therapy, the study was not powered to resolve differences between the two groups.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Article Multidisciplinary Sciences

Markov state modeling reveals alternative unbinding pathways for peptide-MHC complexes

Jayvee R. Abella, Dinler Antunes, Kyle Jackson, Gregory Lizee, Cecilia Clementi, Lydia E. Kavraki

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)

Article Oncology

HLA-Arena: A Customizable Environment for the Structural Modeling and Analysis of Peptide-HLA Complexes for Cancer Immunotherapy

Dinler A. Antunes, Jayvee R. Abella, Sarah Hall-Swan, Didier Devaurs, Anja Conev, Mark Moll, Gregory Lizee, Lydia E. Kavraki

JCO CLINICAL CANCER INFORMATICS (2020)

Article Cell Biology

Using parallelized incremental meta-docking can solve the conformational sampling issue when docking large ligands to proteins

Didier Devaurs, Dinler A. Antunes, Sarah Hall-Swan, Nicole Mitchell, Mark Moll, Gregory Lizee, Lydia E. Kavraki

BMC MOLECULAR AND CELL BIOLOGY (2019)

No Data Available